China Tobacco Hong Kong's 2022 Annual Report

Mar.13.2023
China Tobacco Hong Kong's 2022 Annual Report
China Tobacco Hong Kong's net profit falls 46.66% while new tobacco business sees 10% growth in 2022 fiscal year.

On March 9th, China Tobacco International HK Co. Ltd. released its annual report for the 2022 fiscal year on the Hong Kong stock exchange. According to the report, the company's net profit in 2022 decreased by 46.66% compared to the previous year. However, its new tobacco business saw a 10% increase in sales, and the company's operations in Brazil saw impressive growth.


China Tobacco Hong Kong reported a total operating income of HKD 8.324 billion (approximately RMB 7.3 billion) for the fiscal year 2022, showing a year-on-year growth of 3.23%. However, the net profit attributable to the parent company was HKD 375 million (approximately RMB 330 million), marking a significant decline of 46.66% from the previous year. The basic earnings per share were HKD 0.54.


China Tobacco Hong Kong has explained that the decline in performance is mainly due to weak sales in local cigarette markets in Southeast Asia, caused by increased tobacco taxes and the impact of the pandemic, as well as a weakened demand for tobacco leaves from customers. Additionally, there has been a reduction in suitable tobacco resources available for exportation from China.


Image source: Hong Kong Stock Exchange.


CNTC Hong Kong's new tobacco product exports increased by 47,620 thousand units YoY, accounting for a growth rate of 10%, with total export quantities being 502,390 thousand units. Revenue also increased by HKD 86 million (approximately CNY 75.3 million), resulting in a total revenue of HKD 110 million (approximately CNY 96.33 million), reflecting an 8% increase YoY. However, gross profit decreased by HKD 3.2 million (approximately CNY 2.8 million), representing an 8% decline YoY.


China Tobacco Hong Kong has attributed the growth in sales and revenue of its new tobacco products to its expansion into new markets such as the Middle East, Western Europe, and Eastern Europe. The company has also increased efforts to upgrade its products in response to changing market demands. However, the decrease in profit margin is due to increased investment in marketing resources aimed at gaining more market share.


It is worth mentioning that according to China National Tobacco Corporation Hong Kong's 2022 annual report, its business in Brazil has also grown significantly. Its non-wholly owned subsidiary, CBT, under China National Tobacco Corporation Brazil, exported 29,247 tons of tobacco products to regions outside of China, a year-on-year increase of 33%; revenue was 543 million yuan, a year-on-year increase of 73%; and gross profit was 123 million yuan, a year-on-year increase of 139%.


According to an announcement, China National Tobacco Corporation Hong Kong (CNTC Hong Kong) plans to seize the opportunity presented by the adjustment of China's domestic epidemic prevention policies to continue implementing a dual-wheel development model based on both outward and inward growth. The company will focus on promoting the development of new tobacco product export business and a recovery of cigarette export business.


Reference:


International Chinese cigarette company, limited (Hong Kong) has released their annual report as of December 31, 2022.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
Acme Vape Ltd, the company behind UK vaping brand IVG, has received HM Revenue & Customs approval to operate an excise warehouse for vaping products and participate in the Vaping Duty Stamps Scheme. The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Acme Vape Ltd says its approved warehouse in Preston will become operational under the new regime on the same date.
Regulations
Sep.18 by 2Firsts Perspectives
Product | JNR Launches Shisha Hookah 70K E-Hookah With 60ml E-Liquid and 0.6% Nicotine
Product | JNR Launches Shisha Hookah 70K E-Hookah With 60ml E-Liquid and 0.6% Nicotine
JNR has introduced the Shisha Hookah 70K, a high-capacity rechargeable disposable vape designed around a hookah-inspired experience. The device comes prefilled with 60ml of e-liquid at 6mg/ml (0.6%) nicotine strength, alongside a 1,000mAh rechargeable battery and a 0.38Ω single mesh coil. It also features adjustable airflow and battery and e-liquid level displays. JNR claims the device can deliver up to 70,000 puffs and offers more than 20 flavors. Retail listings for the product have appeared in markets including Tunisia.
Market
Aug.24 by 2Firsts Perspectives
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.
Aug.13
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation party has proposed cutting tobacco excise by 75%, arguing that lower legal cigarette prices could narrow the gap with illicit tobacco and reduce demand for black-market products. The proposal comes as Australia continues expanding enforcement against illicit tobacco supply chains through border controls, retail inspections and organised-crime investigations. Supporters argue high taxes have contributed to illicit-market growth, while opponents warn that lower tobacco prices could undermine public-health goals. The proposal is a party policy position and has not been adopted by the Australian government.
Aug.18
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09